Table 4.
Factors associated with incident liver-related outcomes or death.
| Liver-related outcomes or death Hazard ratios (95% CI) |
p value | |
|---|---|---|
| MRE | ||
| <3.63 kPa (referent) | ref | |
| 3.63–5 kPa | 17.09 (2.38–122.75) | 0.0048 |
| >5 kPa | 16.58 (2.90–94.79) | 0.0016 |
| Demographic and biochemical | ||
| BMI (kg/m2) | 1.02 (0.92–1.13) | 0.6660 |
| HbA1c (%) | 1.69 (0.91–3.14) | 0.0941 |
| AST (U/l) (per 5-unit increase) | 1.17 (1.07–1.28) | 0.0007 |
| ALT (U/l) (per 5-unit increase) | 1.13 (1.05–1.21) | 0.0008 |
| Alkaline phosphatase (U/l) (per 5-unit increase) | 1.11 (0.99–1.26) | 0.0823 |
| Total bilirubin (mg/dl) | 5.90 (1.25–27.82) | 0.0249 |
| Albumin (g/dl) | 0.16 (0.01–1.94) | 0.1512 |
| HOMA-IR | 1.03 (0.98–1.07) | 0.2637 |
| Triglycerides (mg/dl) (per 5-unit increase) | 1.03 (0.99–1.07) | 0.1790 |
| HDL (mg/dl) (per 5-unit increase) | 0.60 (0.40–0.89) | 0.0107 |
| LDL (mg/dl) (per 5-unit increase) | 0.96 (0.86–1.07) | 0.4486 |
| Platelet count (109/l) (per 10-unit increase) | 0.85 (0.76–0.96) | 0.0077 |
| Clinical score | ||
| FIB-4 | 1.94 (1.40–2.68) | <0.0001 |
| NAFLD Fibrosis Score | 1.73 (1.13–2.66) | 0.0115 |
| MELD score (per 1-unit increase) | 1.34 (1.07–1.69) | 0.0122 |
| Positive MEFIB | 21.84 (4.28–111.40) | 0.0002 |
| Imaging | ||
| MRI-PDFF | 1.03 (0.94–1.13) | 0.5187 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FIB-4, fibrosis index based on the 4 factors; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment method for insulin resistance [calculated as (fasting insulin (μU/ml) × fasting glucose (mmol/l)) / 22.5]; INR, international normalized ratio; LDL, low-density lipoprotein; MRI-PDFF, MRI-based proton density fat fraction. Statistically significant p values are denoted in bold.